ASS1 and endometrial cancer: The low expression of argininosuccinate synthetase 1 (ASS1) leads to decreased expression of DEP domain-containing mTOR-interacting protein, an endogenous inhibitor of mTORC1 signal, and thus enhances the activity of the mTORC1 signaling, promoting invasion of endometrial cancer cells [104].